24/7 Market News Snapshot 30 July, 2025 – BioNexus Gene Lab Corp Common stock (NASDAQ:BGLC)

July 30, 2025

DENVER, Colo., 30 July, 2025 (www.247marketnews.com) – (NASDAQ:BGLC) are discussed in this article.
BioNexus Gene Lab Corp. (BGLC) is experiencing remarkable momentum in the pre-market trading session, with shares soaring to $6.577—an impressive increase of 47.47% from the previous close of $4.460. This surge is indicative of robust investor enthusiasm, reflected in a trading volume of 5.39 million shares. The notable price movement suggests a potential wave of momentum, signaling a strong outlook amid positive sentiment prevailing in the biotechnology sector.

In conjunction with this market performance, BGLC has announced a strategic partnership with Fidelion Diagnostics Pte Ltd aimed at revolutionizing liquid biopsy technology for cancer monitoring. This collaboration marks a significant leap in innovation, as BGLC acquires a strategic equity stake in Fidelion, obtaining exclusive commercial rights to the VitaGuard™ platform for detecting minimal residual disease (MRD). The platform represents a breakthrough in non-invasive cancer detection, allowing for early identification of recurrence through a simple blood test, thereby significantly lowering the cost from approximately $3,000 per test to under $300.

Sam Tan, BGLC’s CEO, heralded this partnership as a pivotal advancement in precision oncology, aimed at democratizing access to advanced cancer care across the region. He stated, “By integrating VitaGuard™ into our extensive commercial network, we strive to bring next-generation cancer solutions to millions.” Dr. Yan Linghua, CEO of Fidelion, echoed this sentiment, highlighting the partnership’s potential to dismantle existing cost-accuracy barriers in cancer surveillance and accelerate global commercialization.

As both companies embark on this collaborative journey, they are poised to make significant strides in enhancing patient outcomes and redefining cancer care, with plans for joint development initiatives that include advanced diagnostic programs and AI-driven interventions. The future of cancer monitoring is being reshaped, positioning BGLC and Fidelion at the forefront of this vital industry evolution.

Related news for (BGLC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.